Rittman and colleagues exploited the known distribution of MAPT from the AHBA to examine the relationships between regional tau protein and network level dysfunction in progressive supranuclear palsy (PSP), hypothesising that higher expression would confer greater susceptibility (Rittman et al., 2016). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.